Black Diamond Report First Patient Dosing in a P-I Study of BDTX-1535 for Glioblastoma and Non-Small Cell Lung Cancer
Shots:
- The first patient has been dosed in a P-I study evaluating BDTX-1535 for the treatment of both NSCLC and GBM, derived from Black Diamond’s MAP discovery engine
- The company is expected to advance its BDTX-1535 into the clinic with an expected clinical update in H2’23
- BDTX-1535 is designed as an irreversible, mutant selective, brain-penetrant MasterKey inhibitor of oncogenic mutations of EGFR expressed in GBM and intrinsic and acquired resistance EGFR mutations in NSCLC
Ref: Globe Newswire | Image: PR Newswire
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
